Literature DB >> 19914828

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.

Nicholas Stock1, Christopher Baccei, Gretchen Bain, Alex Broadhead, Charles Chapman, Janice Darlington, Christopher King, Catherine Lee, Yiwei Li, Daniel S Lorrain, Pat Prodanovich, Haojing Rong, Angelina Santini, Jasmine Zunic, Jilly F Evans, John H Hutchinson, Peppi Prasit.   

Abstract

A series of potent 5-lipoxygenase-activating protein (FLAP) inhibitors are herein described. SAR studies focused on the discovery of novel alicyclic moieties appended to an indole core to optimize potency, physical properties and off-target activities. Subsequent SAR on the N-benzyl substituent of the indole led to the discovery of compound 39 (AM679) which showed potent inhibition of leukotrienes in human blood and in a rodent bronchoalvelolar lavage (BAL) challenge model. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914828     DOI: 10.1016/j.bmcl.2009.10.131

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.

Authors:  Gretchen Bain; Christopher D King; Kevin Schaab; Melissa Rewolinski; Virginia Norris; Claire Ambery; Jane Bentley; Masanori Yamada; Angelina M Santini; Jeroen van de Wetering de Rooij; Nicholas Stock; Jasmine Zunic; John H Hutchinson; Jilly F Evans
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.